Ascentage Pharma (AAPG) CMO details options, RSUs and share stakes

Rhea-AI Filing Summary

ASCENTAGE PHARMA GROUP INTERNATIONAL Chief Medical Officer Yifan Zhai filed an initial ownership report listing existing holdings, rather than new trades. The filing shows options and restricted share units over ordinary shares, vesting in four equal parts on each of 11/26/2026, 2027, 2028 and 2029, plus direct and indirect ordinary share positions held through a trust, spouse and HealthQuest Pharma Limited.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Zhai Yifan

(Last) (First) (Middle)

C/O ASCENTAGE PHARMA GROUP INC.

700 KING FARM BLVD., SUITE 510

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
ASCENTAGE PHARMA GROUP INTERNATIONAL [ AAPG ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	1,097,994	I	See Footnote (2)(2)
Ordinary Shares	22,054,131	I	See Footnote (1)(1)
Ordinary Shares	312,534	D
Ordinary Shares	14,089,111	I	See Footnote (5)(5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options	(3)	11/26/2035	Ordinary Shares	143,463	$8.14(4)	I	See Footnote (2)(2)
Options	(3)	11/26/2035	Ordinary Shares	103,364	$8.14(4)	D
Restricted share units	(6)	(6)	Ordinary Shares	143,463	$0	I	See Footnote (2)(2)
Restricted share units	(6)	(6)	Ordinary Shares	103,364	$0	D

Explanation of Responses:

1. Shares held by Dajun Yang Dynasty Trust. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

2. Shares held by Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

3. The stock options vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029.

4. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant.

5. Securities held by ordinary shares held by HealthQuest Pharma Limited, an entity controlled by the Reporting Person. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

6. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029.

Remarks:

This form is filed using a special power of attorney.

	Thomas J. Knapp	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Ascentage Pharma (AAPG) Chief Medical Officer Yifan Zhai report in this Form 3?

The Form 3 reports Zhai’s existing ownership in Ascentage Pharma, not new trades. It lists options, restricted share units, and ordinary shares held directly and indirectly through a trust, spouse, and HealthQuest Pharma Limited, establishing her baseline insider position.

How many Ascentage Pharma (AAPG) options does Yifan Zhai hold and when do they vest?

The filing shows options linked to 143,463 ordinary shares indirectly and 103,364 directly at an exercise price of 8.1400. Footnotes state these stock options vest in four equal increments on each of 11/26/2026, 11/26/2027, 11/26/2028 and 11/26/2029.

What restricted share units does Ascentage Pharma (AAPG) CMO Yifan Zhai own?

Zhai holds restricted share units tied to 143,463 ordinary shares indirectly and 103,364 directly. Each RSU represents a contingent right to receive one ordinary share, with vesting in four equal increments on 11/26/2026, 11/26/2027, 11/26/2028 and 11/26/2029, according to the footnotes.

How are some of Yifan Zhai’s Ascentage Pharma (AAPG) shares held indirectly?

Certain ordinary shares are held by the Dajun Yang Dynasty Trust, by her spouse, and by HealthQuest Pharma Limited, which she controls. The filing states she disclaims beneficial ownership beyond her pecuniary interest, even though these indirect positions are included in the ownership report.

When do Yifan Zhai’s Ascentage Pharma (AAPG) options expire and in what currency is the exercise price?

The options tied to ordinary shares expire on 11/26/2035. A footnote explains the exercise price is set in HKD, and the 8.1400 figure shown reflects conversion to USD based on the exchange rate on the grant date.

Does this Ascentage Pharma (AAPG) Form 3 show any insider buying or selling by Yifan Zhai?

The data classify all entries as holdings with unknown transaction codes, and the summary shows zero buys or sells. This indicates the Form 3 serves as an initial statement of beneficial ownership, not a record of new purchase or sale activity.